Professor Barry Gusterson

  • Honorary Senior Research Fellow (Institute of Cancer Sciences)

email: Barry.Gusterson@glasgow.ac.uk

R227 Level 2, Department of Pathology, Mcgregor Building, Western Infirmary G11 6NT

Publications

List by: Type | Date

Jump to: 2018 | 2017 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000
Number of items: 81.

2018

Gusterson, B. and Eaves, C. J. (2018) Basal-like breast cancers: from pathology to biology and back again. Stem Cell Reports, 10(6), pp. 1676-1686. (doi: 10.1016/j.stemcr.2018.04.023) (PMID:29874626) (PMCID:PMC6117459)

2017

Soady, K. J., Tornillo, G., Kendrick, H., Meniel, V., Olijnyk-Dallis, D., Morris, J. S. , Stein, T., Gusterson, B. A., Isacke, C. M. and Smalley, M. J. (2017) The receptor protein tyrosine phosphatase PTPRB negatively regulates FGF2-dependent branching morphogenesis. Development, 144(20), pp. 3777-3788. (doi: 10.1242/dev.149120) (PMID:28870991)

2015

Munzone, E. et al. (2015) Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Annals of Oncology, 26(12), pp. 2442-2449. (doi: 10.1093/annonc/mdv391) (PMID:26387144)

Metzger Filho, O. et al. (2015) Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology, 33(25), pp. 2772-2779. (doi: 10.1200/jco.2015.60.8133) (PMID:26215945)

2014

Olijnyk, D., Ibrahim, A.M., Ferrier, R.K., Tsuda, T., Chu, M.-L., Gusterson, B.A., Stein, T. and Morris, J.S. (2014) Fibulin-2 is involved in early extracellular matrix development of the outgrowing mouse mammary epithelium. Cellular and Molecular Life Sciences, 71(19), pp. 3811-3828. (doi: 10.1007/s00018-014-1577-4)

McDonald, L. et al. (2014) RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland. Disease Models and Mechanisms, 7(5), pp. 525-534. (doi: 10.1242/dmm.015040)

2013

Karim, S.A., Creedon, H., Patel, H., Carragher, N.O., Morton, J.P. , Muller, W.J., Evans, T.R.J. , Gusterson, B., Sansom, O.J. and Brunton, V.G. (2013) Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. Journal of Pathology, 230(4), pp. 430-440. (doi: 10.1002/path.4202)

2012

Gusterson, B.A. and Stein, T. (2012) Human breast development. Seminars in Cell and Developmental Biology, 23(5), pp. 567-573. (doi: 10.1016/j.semcdb.2012.03.013)

Eiermann, W. et al. (2012) Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast, 21(1), pp. 20-26. (doi: 10.1016/j.breast.2011.09.006)

2011

Karlsson, P. et al. (2011) Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Annals of Oncology, 22(10), pp. 2216-2226. (doi: 10.1093/annonc/mdq735)

Aebi, S. et al. (2011) Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. Annals of Oncology, 22(9), pp. 1981-1987. (doi: 10.1093/annonc/mdq754)

Viale, G. et al. (2011) Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Annals of Oncology, 22(10), pp. 2201-2207. (doi: 10.1093/annonc/mdq738)

2010

Colleoni, M. et al. (2010) Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. Journal of Clinical Oncology, 28(18), pp. 2966-2973. (doi: 10.1200/JCO.2009.25.9549)

Fernandez-Twinn, D.S., Ekizoglou, S., Martin-Gronert, M. S., Tarry-Adkins, J., Wayman, A. P., Warner, M. J., Luan, J.- A., Gusterson, B.A. and Ozanne, S.E. (2010) Poor early growth and excessive adult calorie intake independently and additively affect mitogenic signaling and increase mammary tumor susceptibility. Carcinogenesis, 31(10), pp. 1873-1881. (doi: 10.1093/carcin/bgq095)

Huser, C.A., Pringle, M.A., Heath, V.J., Bell, A.K., Kendrick, H., Smalley, M.J., Crighton, D., Ryan, K.M. , Gusterson, B.A. and Stein, T. (2010) TSC-22D1 isoforms have opposing roles in mammary epithelial cell survival. Cell Death and Differentiation, 17(2), pp. 304-315. (doi: 10.1038/cdd.2009.126)

Stein, T. et al. (2010) Loss of Reelin Expression in Breast Cancer Is Epigenetically Controlled and Associated with Poor Prognosis. American Journal of Pathology, 177(5), pp. 2323-2333. (doi: 10.2353/ajpath.2010.100209)

Viale, G. et al. (2010) Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Annals of Oncology, 21(2), pp. 245-254. (doi: 10.1093/annonc/mdp317)

Watson, C.J. and Gusterson, B.A. (2010) A prophylactic vaccine for breast cancer? Breast Cancer Research, 12(4), p. 310. (doi: 10.1186/bcr2628)

2009

(BIG) 1-98 Collaborative Group, (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of Oncology, 20(9), pp. 1489-1498. (doi: 10.1093/annonc/mdp033)

(BIG) 1-98 Collaborative Group, (2009) Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clinical Trials, 6(3), pp. 272-287. (doi: 10.1177/1740774509105380)

BIG 1-98 Collaborative Group, (2009) Letrozole therapy alone or in sequence with Tamoxifen in women with breast cancer. New England Journal of Medicine, 361(8), pp. 766-776. (doi: 10.1056/NEJMoa0810818)

Gusterson, B. (2009) Do 'basal-like' breast cancers really exist? Nature Reviews Cancer, 9(2), pp. 128-134. (doi: 10.1038/nrc2571)

Gusterson, B. and Hunter, K. (2009) Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncology, 10(5), pp. 522-527.

International Breast Cancer Study Group, (2009) Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93. Breast Cancer Research and Treatment, 116(3), pp. 491-500. (doi: 10.1007/s10549-008-0225-9)

International Breast Cancer Study Group, (2009) The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Annals of Oncology, 20(8), pp. 1344-1351. (doi: 10.1093/annonc/mdp024)

Stein, T., Salomonis, N., Nuyten, D., van de Vijver, M. and Gusterson, B. (2009) A Mouse Mammary Gland Involution mRNA Signature Identifies Biological Pathways Potentially Associated with Breast Cancer Metastasis. Journal of Mammary Gland Biology and Neoplasia, 14(2), pp. 99-116. (doi: 10.1007/s10911-009-9120-1)

2008

Gruber, G. et al. (2008) Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Annals of Oncology, 19(8), pp. 1393-1401. (doi: 10.1093/annonc/mdn123)

Pestalozzi, B. et al. (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials. Journal of Clinical Oncology, 26(18), pp. 3006-3014. (doi: 10.1200/JCO.2007.14.9336)

Rasmussen, B.B. et al. (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncology, 9(1), pp. 23-28. (doi: 10.1016/S1470-2045(07)70386-8)

Ravaioli, A. et al. (2008) p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Annals of Oncology, 19(4), pp. 660-668. (doi: 10.1093/annonc/mdm547)

Viale, G. et al. (2008) Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group. Journal of Clinical Oncology, 26(9), pp. 1404-1410. (doi: 10.1200/JCO.2007.10.6393)

Viale, G. et al. (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. Journal of the National Cancer Institute, 100(3), pp. 207-212. (doi: 10.1093/jnci/djm289)

Viale, G. et al. (2008) Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole. Journal of Clinical Oncology, 26(34), pp. 5569-5575. (doi: 10.1200/JCO.2008.17.0829)

2007

Locke, D., Jamieson, S. , Stein, T., Liu, J., Hodgkins, M.B., Harris, A.L. and Gusterson, B. (2007) Nature of Cx30-containing channels in the adult mouse mammary gland. Cell and Tissue Research, 328(1), pp. 97-107. (doi: 10.1007/s00441-006-0301-6)

Fernandez-Twinn, D., Ekizoglou, S., Gusterson, B., Luan, J. and Ozanne, S. (2007) Compensatory mammary growth following protein restriction during pregnancy and lactation increases early-onset mammary tumor incidence in rats. Carcinogenesis, 28, pp. 545-552. (doi: 10.1093/carcin/bgl166)

Karlsson, P. et al. (2007) The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. Journal of Clinical Oncology, 25, pp. 2019-2026. (doi: 10.1200/JCO.2006.09.8152)

Kote-Jarai, Z. et al. (2007) BRCA1/BRCA2 mutation status and analysis of cancer family history in Participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Letters, 247, pp. 259-265. (doi: 10.1016/j.canlet.2006.05.003)

Stein, T., Salomonis, N. and Gusterson, B. (2007) Mammary gland involution as a multi-step process. Journal of Mammary Gland Biology and Neoplasia, 12, pp. 25-35. (doi: 10.1007/s10911-007-9035-7)

Viale, G. et al. (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. Journal of Clinical Oncology, 25, pp. 3846-3852. (doi: 10.1200/JCO.2007.11.9453)

2006

Morris, J.S. , Stein, T., Pringle, M.A., Davies, C.R., Weber-Hall, S., Ferrier, R.K., Bell, A.K., Heath, V.J. and Gusterson, B.A. (2006) Involvement of axonal guidance proteins and their signaling partners in the developing mouse mammary gland. Journal of Cellular Physiology, 206(1), pp. 16-24. (doi: 10.1002/jcp.20427)

Davies, C. R., Morris, J. S. , Griffiths, M. R., Page, M. J., Pitt, A., Stein, T. and Gusterson, B. A. (2006) Proteomic analysis of the mouse mammary gland is a powerful tool to identify novel proteins that are differentially expressed during mammary development. Proteomics, 6(21), pp. 5694-5704. (doi: 10.1002/pmic.200600202)

International Breast Cancer Study Group, (2006) Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93. Journal of Clinical Oncology, 24(3), pp. 337-344. (doi: 10.1200/JCO.2005.01.5784)

Regan, M. et al. (2006) Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. Journal of the National Cancer Institute, 98, pp. 1571-1581. (doi: 10.1093/jnci/djj415)

2005

Gusterson, B.A., Ross, D.T., Heath, V.J. and Stein, T. (2005) Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Research, 7(4), pp. 143-148. (doi: 10.1186/bcr1041)

Hagan, S., Al-Mulla, F., Mallon, E., Oien, K. , Ferrier, R., Gusterson, B., Garcia, J. and Kolch, W. (2005) Reduction of raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clinical Cancer Research, 11(20), pp. 7392-7397. (doi: 10.1158/1078-0432.CCR-05-0283)

Lakhani, S. R. et al. (2005) Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype. Clinical Cancer Research, 11(14), pp. 5175-5180. (doi: 10.1158/1078-0432.CCR-04-2424)

Stein, T. et al. (2005) Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. Clinical Cancer Research, 11(19), pp. 6872-6879. (doi: 10.1158/1078-0432.CCR-05-0547)

2004

International Breast Cancer Study Group, (2004) Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Annals of Oncology, 15(12), pp. 1749-1759. (doi: 10.1093/annonc/mdh463)

Kote-Jarai, Z. et al. (2004) Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. Clinical Cancer Research, 10(3), pp. 958-963. (doi: 10.1158/1078-0432.CCR-1067-3)

Locke, D., Stein, T., Davies, C., Morris, J. , Harris, A., Evans, W., Monaghan, P. and Gusterson, B. (2004) Altered permeability and modulatory character of connexin channels during mammary gland development. Experimental Cell Research, 298(2), pp. 643-660. (doi: 10.1016/j.yexcr.2004.05.003)

Morris, J. , Davies, C., Griffiths, M., Page, M., Bruce, J., Patel, G., Herath, A. and Gusterson, B. (2004) Proteomic analysis of mouse mammary terminal end buds identifies axonal growth cone proteins. Proteomics, 4(6), pp. 1802-1810. (doi: 10.1002/pmic.200300699)

Stein, T., Morris, J.S., Davies, C.R., Weber-Hall, S.J., Duffy, M.A., Heath, V.J., Bell, A.K., Ferrier, R.K., Sandilands, G.P. and Gusterson, B.A. (2004) Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Research, 6(2), R75-R91.

Yap, D., Hsieh, J., Zhong, S., Heath, V., Gusterson, B., Crook, T. and Lu, X. (2004) Ser(392) phosphorylation regulates the oncogenic function of mutant p53. Cancer Research, 64(14), pp. 4749-4754. (doi: 10.1158/0008-5472.CAN-1305-2)

2003

Hair, J., McNicol, A. and Gusterson, B. (2003) Is research on human tissues at a crossroads? European Journal of Cancer, 39(16), pp. 2253-2255. (doi: 10.1016/S0959-8049(03)00670-1)

Spataro, V. et al. (2003) Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status - Results from International Breast Cancer Study Group Trial V. Cancer, 97(7), pp. 1591-1600. (doi: 10.1002/cncr.11224)

Bergamaschi, D. et al. (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3(4), pp. 387-402.

Fernandez-Twinn, D., Ozanne, S., Ekizoglou, S., Doherty, C., James, L., Gusterson, B. and Hales, C. (2003) The maternal endocrine environment in the low-protein model of intra-uterine growth restriction. British Journal of Nutrition, 90(4), pp. 815-822. (doi: 10.1079/BJN2003967)

Gusterson, B.A., Cui, W. and Clark, A.K. (2003) Development of novel selective cell ablation in the mammary gland and to study cell-cell interactions and chemoprevention. In: Senn, H.J. and Morant, R. (eds.) Tumor Prevention and Genetics. Series: Recent Results in Cancer Research (163). Springer: Berlin, Germany, pp. 31-45. ISBN 9783540440628

Gusterson, B. (2003) The new TNM classification and micrometastases. Breast, 12(6), pp. 387-390. (doi: 10.1016/S0960-9776(03)00141-3)

Osin, P., Lu, Y., Stone, J., Crook, T., Houlston, R., Gasco, M., Gusterson, B. and Shipley, J. (2003) Distinct genetic and epigenetic changes in medullary breast cancer. International Journal of Surgical Pathology, 11(3), pp. 153-158. (doi: 10.1177/106689690301100301)

Trihia, H., Murray, S., Price, K., Gelber, R., Golouh, R., Goldhirsch, A., Coates, A., Collins, J., Castiglione-Gertsch, M. and Gusterson, B. (2003) Ki-67 expression in breast carcinoma - Its association with grading systems, clinical parameters, and other prognostic factors - A surrogate marker? Cancer, 97, pp. 1321-1331. (doi: 10.1002/cncr.11188)

2002

Baltayan, A., Naritoku, W., Chaiwun, B., Tsao-Wei, D., Groshen, S., Hern, R., Gusterson, B., Taylor, C. and Imam, S. (2002) LEA.135 expression: Identifies low-risk patients with breast ductal carcinoma in situ. Anticancer Research, 22(5), pp. 2933-2937.

Brooks, L. et al. (2002) E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. British Journal of Cancer, 86(2), pp. 263-268. (doi: 10.1038/sj/bjc/6600033)

Cui, W., Gusterson, B. and Clark, A. (2002) Inhibition of myc-dependent breast tumor formation in transgenic mice. Breast Cancer Research and Treatment, 71(1), pp. 9-20. (doi: 10.1023/A:1013334013065)

Davies, H. et al. (2002) Mutations of the BRAF gene in human cancer. Nature, 417(6892), pp. 949-954. (doi: 10.1038/nature00766)

Gasco, M. et al. (2002) Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: Association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Research, 62(7), pp. 2072-2076.

Gasco, M., Sullivan, A., Repellin, C., Brooks, L., Farrell, P., Tidy, J., Dunne, B., Gusterson, B., Evans, D. and Crook, T. (2002) Coincident inactivation of 14-3-3 sigma and p16(INK4a) is an early event in vulval squamous neoplasia. Oncogene, 21(12), pp. 1876-1881. (doi: 10.1038/sj.onc.1205256)

International Breast Cancer Study Group (IBCSG), (2002) Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. Journal of the National Cancer Institute, 94(14), pp. 1054-1065. (doi: 10.1093/jnci/94.14.1054)

Prince, J., Klinowska, T., Marshman, E., Lowe, E., Mayer, U., Miner, J., Aberdam, D., Vestweber, D., Gusterson, B. and Streuli, C. (2002) Cell-matrix interactions during development and apoptosis of the mouse mammary gland in vivo. Developmental Dynamics, 223(4), pp. 497-516. (doi: 10.1002/dvdy.10070)

Reddy, A. et al. (2002) Analysis of CHK2 in vulval neoplasia. British Journal of Cancer, 86(5), pp. 756-760. (doi: 10.1038/sj/bjc/6600131)

Sullivan, A. et al. (2002) Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene, 21(9), pp. 1316-1324. (doi: 10.1038/sj/onc/1205207)

2001

Going, J., Mallon, E., Leake, R., Bartlett, J. and Gusterson, B. (2001) What the clinician needs from the pathologist: evidence-based reporting in breast cancer. European Journal of Cancer, 37(Suppl.), S5-S17.

Cui, W., Allen, N., Skynner, M., Gusterson, B. and Clark, A. (2001) Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain. Glia, 34(4), pp. 272-282. (doi: 10.1002/glia.1061)

Hedenfalk, I. et al. (2001) Gene-expression profiles in hereditary breast cancer. New England Journal of Medicine, 344(8), pp. 539-548. (doi: 10.1056/NEJM200102223440801)

Kitchen, P., Smith, H., Henderson, M., Goldhirsch, A., Castiglione-Gertsch, M., Coates, A., Gusterson, B., Brown, R., Gelber, R. and Collins, J. (2001) Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy. Australian and New Zealand Journal of Surgery, 71(1), pp. 27-31. (doi: 10.1046/j.1440-1622.2001.02022.x)

O'Nions, J. et al. (2001) p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. British Journal of Cancer, 85(10), pp. 1551-1556. (doi: 10.1054/bjoc.2001.2138)

Stone, J. et al. (2001) Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in situ of the breast. Cancer Letters, 167(2), pp. 171-174. (doi: 10.1016/S0304-3835(01)00448-7)

2000

Brooks, L., Tidy, J., Gusterson, B., Hiller, L., O'Nions, J., Gasco, M., Marin, M., Farrell, P., Kaelin, W. and Crook, T. (2000) Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Research, 60(24), pp. 6875-6877.

Ellis, I.O., Dowsett, M., Bartlett, J., Walker, R., Cooke, T., Gullick, W., Gusterson, B., Mallon, E. and Lee, P.B. (2000) Recommendations for HER2 testing in the UK. Journal of Clinical Pathology, 53(12), pp. 890-892.

Gusterson, B. and Howard, B. (2000) Human breast development. Journal of Mammary Gland Biology and Neoplasia, 5(2), pp. 119-137. (doi: 10.1023/A:1026487120779)

Mallon, E., Osin, P., Nasiri, N., Blain, I., Howard, B. and Gusterson, B. (2000) The basic pathology of human breast cancer. Journal of Mammary Gland Biology and Neoplasia, 5(2), pp. 139-163. (doi: 10.1023/A:1026439204849)

This list was generated on Thu Sep 17 14:07:54 2020 BST.
Number of items: 81.

Articles

Gusterson, B. and Eaves, C. J. (2018) Basal-like breast cancers: from pathology to biology and back again. Stem Cell Reports, 10(6), pp. 1676-1686. (doi: 10.1016/j.stemcr.2018.04.023) (PMID:29874626) (PMCID:PMC6117459)

Soady, K. J., Tornillo, G., Kendrick, H., Meniel, V., Olijnyk-Dallis, D., Morris, J. S. , Stein, T., Gusterson, B. A., Isacke, C. M. and Smalley, M. J. (2017) The receptor protein tyrosine phosphatase PTPRB negatively regulates FGF2-dependent branching morphogenesis. Development, 144(20), pp. 3777-3788. (doi: 10.1242/dev.149120) (PMID:28870991)

Munzone, E. et al. (2015) Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. Annals of Oncology, 26(12), pp. 2442-2449. (doi: 10.1093/annonc/mdv391) (PMID:26387144)

Metzger Filho, O. et al. (2015) Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial. Journal of Clinical Oncology, 33(25), pp. 2772-2779. (doi: 10.1200/jco.2015.60.8133) (PMID:26215945)

Olijnyk, D., Ibrahim, A.M., Ferrier, R.K., Tsuda, T., Chu, M.-L., Gusterson, B.A., Stein, T. and Morris, J.S. (2014) Fibulin-2 is involved in early extracellular matrix development of the outgrowing mouse mammary epithelium. Cellular and Molecular Life Sciences, 71(19), pp. 3811-3828. (doi: 10.1007/s00018-014-1577-4)

McDonald, L. et al. (2014) RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland. Disease Models and Mechanisms, 7(5), pp. 525-534. (doi: 10.1242/dmm.015040)

Karim, S.A., Creedon, H., Patel, H., Carragher, N.O., Morton, J.P. , Muller, W.J., Evans, T.R.J. , Gusterson, B., Sansom, O.J. and Brunton, V.G. (2013) Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. Journal of Pathology, 230(4), pp. 430-440. (doi: 10.1002/path.4202)

Gusterson, B.A. and Stein, T. (2012) Human breast development. Seminars in Cell and Developmental Biology, 23(5), pp. 567-573. (doi: 10.1016/j.semcdb.2012.03.013)

Eiermann, W. et al. (2012) Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast, 21(1), pp. 20-26. (doi: 10.1016/j.breast.2011.09.006)

Karlsson, P. et al. (2011) Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Annals of Oncology, 22(10), pp. 2216-2226. (doi: 10.1093/annonc/mdq735)

Aebi, S. et al. (2011) Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX. Annals of Oncology, 22(9), pp. 1981-1987. (doi: 10.1093/annonc/mdq754)

Viale, G. et al. (2011) Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Annals of Oncology, 22(10), pp. 2201-2207. (doi: 10.1093/annonc/mdq738)

Colleoni, M. et al. (2010) Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer. Journal of Clinical Oncology, 28(18), pp. 2966-2973. (doi: 10.1200/JCO.2009.25.9549)

Fernandez-Twinn, D.S., Ekizoglou, S., Martin-Gronert, M. S., Tarry-Adkins, J., Wayman, A. P., Warner, M. J., Luan, J.- A., Gusterson, B.A. and Ozanne, S.E. (2010) Poor early growth and excessive adult calorie intake independently and additively affect mitogenic signaling and increase mammary tumor susceptibility. Carcinogenesis, 31(10), pp. 1873-1881. (doi: 10.1093/carcin/bgq095)

Huser, C.A., Pringle, M.A., Heath, V.J., Bell, A.K., Kendrick, H., Smalley, M.J., Crighton, D., Ryan, K.M. , Gusterson, B.A. and Stein, T. (2010) TSC-22D1 isoforms have opposing roles in mammary epithelial cell survival. Cell Death and Differentiation, 17(2), pp. 304-315. (doi: 10.1038/cdd.2009.126)

Stein, T. et al. (2010) Loss of Reelin Expression in Breast Cancer Is Epigenetically Controlled and Associated with Poor Prognosis. American Journal of Pathology, 177(5), pp. 2323-2333. (doi: 10.2353/ajpath.2010.100209)

Viale, G. et al. (2010) Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Annals of Oncology, 21(2), pp. 245-254. (doi: 10.1093/annonc/mdp317)

Watson, C.J. and Gusterson, B.A. (2010) A prophylactic vaccine for breast cancer? Breast Cancer Research, 12(4), p. 310. (doi: 10.1186/bcr2628)

(BIG) 1-98 Collaborative Group, (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of Oncology, 20(9), pp. 1489-1498. (doi: 10.1093/annonc/mdp033)

(BIG) 1-98 Collaborative Group, (2009) Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clinical Trials, 6(3), pp. 272-287. (doi: 10.1177/1740774509105380)

BIG 1-98 Collaborative Group, (2009) Letrozole therapy alone or in sequence with Tamoxifen in women with breast cancer. New England Journal of Medicine, 361(8), pp. 766-776. (doi: 10.1056/NEJMoa0810818)

Gusterson, B. (2009) Do 'basal-like' breast cancers really exist? Nature Reviews Cancer, 9(2), pp. 128-134. (doi: 10.1038/nrc2571)

Gusterson, B. and Hunter, K. (2009) Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncology, 10(5), pp. 522-527.

International Breast Cancer Study Group, (2009) Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93. Breast Cancer Research and Treatment, 116(3), pp. 491-500. (doi: 10.1007/s10549-008-0225-9)

International Breast Cancer Study Group, (2009) The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Annals of Oncology, 20(8), pp. 1344-1351. (doi: 10.1093/annonc/mdp024)

Stein, T., Salomonis, N., Nuyten, D., van de Vijver, M. and Gusterson, B. (2009) A Mouse Mammary Gland Involution mRNA Signature Identifies Biological Pathways Potentially Associated with Breast Cancer Metastasis. Journal of Mammary Gland Biology and Neoplasia, 14(2), pp. 99-116. (doi: 10.1007/s10911-009-9120-1)

Gruber, G. et al. (2008) Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Annals of Oncology, 19(8), pp. 1393-1401. (doi: 10.1093/annonc/mdn123)

Pestalozzi, B. et al. (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: Combined results of 15 International Breast Cancer Study Group clinical trials. Journal of Clinical Oncology, 26(18), pp. 3006-3014. (doi: 10.1200/JCO.2007.14.9336)

Rasmussen, B.B. et al. (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncology, 9(1), pp. 23-28. (doi: 10.1016/S1470-2045(07)70386-8)

Ravaioli, A. et al. (2008) p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Annals of Oncology, 19(4), pp. 660-668. (doi: 10.1093/annonc/mdm547)

Viale, G. et al. (2008) Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group. Journal of Clinical Oncology, 26(9), pp. 1404-1410. (doi: 10.1200/JCO.2007.10.6393)

Viale, G. et al. (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. Journal of the National Cancer Institute, 100(3), pp. 207-212. (doi: 10.1093/jnci/djm289)

Viale, G. et al. (2008) Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole. Journal of Clinical Oncology, 26(34), pp. 5569-5575. (doi: 10.1200/JCO.2008.17.0829)

Locke, D., Jamieson, S. , Stein, T., Liu, J., Hodgkins, M.B., Harris, A.L. and Gusterson, B. (2007) Nature of Cx30-containing channels in the adult mouse mammary gland. Cell and Tissue Research, 328(1), pp. 97-107. (doi: 10.1007/s00441-006-0301-6)

Fernandez-Twinn, D., Ekizoglou, S., Gusterson, B., Luan, J. and Ozanne, S. (2007) Compensatory mammary growth following protein restriction during pregnancy and lactation increases early-onset mammary tumor incidence in rats. Carcinogenesis, 28, pp. 545-552. (doi: 10.1093/carcin/bgl166)

Karlsson, P. et al. (2007) The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. Journal of Clinical Oncology, 25, pp. 2019-2026. (doi: 10.1200/JCO.2006.09.8152)

Kote-Jarai, Z. et al. (2007) BRCA1/BRCA2 mutation status and analysis of cancer family history in Participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer Letters, 247, pp. 259-265. (doi: 10.1016/j.canlet.2006.05.003)

Stein, T., Salomonis, N. and Gusterson, B. (2007) Mammary gland involution as a multi-step process. Journal of Mammary Gland Biology and Neoplasia, 12, pp. 25-35. (doi: 10.1007/s10911-007-9035-7)

Viale, G. et al. (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. Journal of Clinical Oncology, 25, pp. 3846-3852. (doi: 10.1200/JCO.2007.11.9453)

Morris, J.S. , Stein, T., Pringle, M.A., Davies, C.R., Weber-Hall, S., Ferrier, R.K., Bell, A.K., Heath, V.J. and Gusterson, B.A. (2006) Involvement of axonal guidance proteins and their signaling partners in the developing mouse mammary gland. Journal of Cellular Physiology, 206(1), pp. 16-24. (doi: 10.1002/jcp.20427)

Davies, C. R., Morris, J. S. , Griffiths, M. R., Page, M. J., Pitt, A., Stein, T. and Gusterson, B. A. (2006) Proteomic analysis of the mouse mammary gland is a powerful tool to identify novel proteins that are differentially expressed during mammary development. Proteomics, 6(21), pp. 5694-5704. (doi: 10.1002/pmic.200600202)

International Breast Cancer Study Group, (2006) Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93. Journal of Clinical Oncology, 24(3), pp. 337-344. (doi: 10.1200/JCO.2005.01.5784)

Regan, M. et al. (2006) Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. Journal of the National Cancer Institute, 98, pp. 1571-1581. (doi: 10.1093/jnci/djj415)

Gusterson, B.A., Ross, D.T., Heath, V.J. and Stein, T. (2005) Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Research, 7(4), pp. 143-148. (doi: 10.1186/bcr1041)

Hagan, S., Al-Mulla, F., Mallon, E., Oien, K. , Ferrier, R., Gusterson, B., Garcia, J. and Kolch, W. (2005) Reduction of raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clinical Cancer Research, 11(20), pp. 7392-7397. (doi: 10.1158/1078-0432.CCR-05-0283)

Lakhani, S. R. et al. (2005) Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype. Clinical Cancer Research, 11(14), pp. 5175-5180. (doi: 10.1158/1078-0432.CCR-04-2424)

Stein, T. et al. (2005) Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. Clinical Cancer Research, 11(19), pp. 6872-6879. (doi: 10.1158/1078-0432.CCR-05-0547)

International Breast Cancer Study Group, (2004) Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Annals of Oncology, 15(12), pp. 1749-1759. (doi: 10.1093/annonc/mdh463)

Kote-Jarai, Z. et al. (2004) Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. Clinical Cancer Research, 10(3), pp. 958-963. (doi: 10.1158/1078-0432.CCR-1067-3)

Locke, D., Stein, T., Davies, C., Morris, J. , Harris, A., Evans, W., Monaghan, P. and Gusterson, B. (2004) Altered permeability and modulatory character of connexin channels during mammary gland development. Experimental Cell Research, 298(2), pp. 643-660. (doi: 10.1016/j.yexcr.2004.05.003)

Morris, J. , Davies, C., Griffiths, M., Page, M., Bruce, J., Patel, G., Herath, A. and Gusterson, B. (2004) Proteomic analysis of mouse mammary terminal end buds identifies axonal growth cone proteins. Proteomics, 4(6), pp. 1802-1810. (doi: 10.1002/pmic.200300699)

Stein, T., Morris, J.S., Davies, C.R., Weber-Hall, S.J., Duffy, M.A., Heath, V.J., Bell, A.K., Ferrier, R.K., Sandilands, G.P. and Gusterson, B.A. (2004) Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Research, 6(2), R75-R91.

Yap, D., Hsieh, J., Zhong, S., Heath, V., Gusterson, B., Crook, T. and Lu, X. (2004) Ser(392) phosphorylation regulates the oncogenic function of mutant p53. Cancer Research, 64(14), pp. 4749-4754. (doi: 10.1158/0008-5472.CAN-1305-2)

Hair, J., McNicol, A. and Gusterson, B. (2003) Is research on human tissues at a crossroads? European Journal of Cancer, 39(16), pp. 2253-2255. (doi: 10.1016/S0959-8049(03)00670-1)

Spataro, V. et al. (2003) Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status - Results from International Breast Cancer Study Group Trial V. Cancer, 97(7), pp. 1591-1600. (doi: 10.1002/cncr.11224)

Bergamaschi, D. et al. (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3(4), pp. 387-402.

Fernandez-Twinn, D., Ozanne, S., Ekizoglou, S., Doherty, C., James, L., Gusterson, B. and Hales, C. (2003) The maternal endocrine environment in the low-protein model of intra-uterine growth restriction. British Journal of Nutrition, 90(4), pp. 815-822. (doi: 10.1079/BJN2003967)

Gusterson, B. (2003) The new TNM classification and micrometastases. Breast, 12(6), pp. 387-390. (doi: 10.1016/S0960-9776(03)00141-3)

Osin, P., Lu, Y., Stone, J., Crook, T., Houlston, R., Gasco, M., Gusterson, B. and Shipley, J. (2003) Distinct genetic and epigenetic changes in medullary breast cancer. International Journal of Surgical Pathology, 11(3), pp. 153-158. (doi: 10.1177/106689690301100301)

Trihia, H., Murray, S., Price, K., Gelber, R., Golouh, R., Goldhirsch, A., Coates, A., Collins, J., Castiglione-Gertsch, M. and Gusterson, B. (2003) Ki-67 expression in breast carcinoma - Its association with grading systems, clinical parameters, and other prognostic factors - A surrogate marker? Cancer, 97, pp. 1321-1331. (doi: 10.1002/cncr.11188)

Baltayan, A., Naritoku, W., Chaiwun, B., Tsao-Wei, D., Groshen, S., Hern, R., Gusterson, B., Taylor, C. and Imam, S. (2002) LEA.135 expression: Identifies low-risk patients with breast ductal carcinoma in situ. Anticancer Research, 22(5), pp. 2933-2937.

Brooks, L. et al. (2002) E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. British Journal of Cancer, 86(2), pp. 263-268. (doi: 10.1038/sj/bjc/6600033)

Cui, W., Gusterson, B. and Clark, A. (2002) Inhibition of myc-dependent breast tumor formation in transgenic mice. Breast Cancer Research and Treatment, 71(1), pp. 9-20. (doi: 10.1023/A:1013334013065)

Davies, H. et al. (2002) Mutations of the BRAF gene in human cancer. Nature, 417(6892), pp. 949-954. (doi: 10.1038/nature00766)

Gasco, M. et al. (2002) Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: Association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Research, 62(7), pp. 2072-2076.

Gasco, M., Sullivan, A., Repellin, C., Brooks, L., Farrell, P., Tidy, J., Dunne, B., Gusterson, B., Evans, D. and Crook, T. (2002) Coincident inactivation of 14-3-3 sigma and p16(INK4a) is an early event in vulval squamous neoplasia. Oncogene, 21(12), pp. 1876-1881. (doi: 10.1038/sj.onc.1205256)

International Breast Cancer Study Group (IBCSG), (2002) Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized Trial. Journal of the National Cancer Institute, 94(14), pp. 1054-1065. (doi: 10.1093/jnci/94.14.1054)

Prince, J., Klinowska, T., Marshman, E., Lowe, E., Mayer, U., Miner, J., Aberdam, D., Vestweber, D., Gusterson, B. and Streuli, C. (2002) Cell-matrix interactions during development and apoptosis of the mouse mammary gland in vivo. Developmental Dynamics, 223(4), pp. 497-516. (doi: 10.1002/dvdy.10070)

Reddy, A. et al. (2002) Analysis of CHK2 in vulval neoplasia. British Journal of Cancer, 86(5), pp. 756-760. (doi: 10.1038/sj/bjc/6600131)

Sullivan, A. et al. (2002) Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene, 21(9), pp. 1316-1324. (doi: 10.1038/sj/onc/1205207)

Going, J., Mallon, E., Leake, R., Bartlett, J. and Gusterson, B. (2001) What the clinician needs from the pathologist: evidence-based reporting in breast cancer. European Journal of Cancer, 37(Suppl.), S5-S17.

Cui, W., Allen, N., Skynner, M., Gusterson, B. and Clark, A. (2001) Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain. Glia, 34(4), pp. 272-282. (doi: 10.1002/glia.1061)

Hedenfalk, I. et al. (2001) Gene-expression profiles in hereditary breast cancer. New England Journal of Medicine, 344(8), pp. 539-548. (doi: 10.1056/NEJM200102223440801)

Kitchen, P., Smith, H., Henderson, M., Goldhirsch, A., Castiglione-Gertsch, M., Coates, A., Gusterson, B., Brown, R., Gelber, R. and Collins, J. (2001) Tubular carcinoma of the breast: Prognosis and response to adjuvant systemic therapy. Australian and New Zealand Journal of Surgery, 71(1), pp. 27-31. (doi: 10.1046/j.1440-1622.2001.02022.x)

O'Nions, J. et al. (2001) p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. British Journal of Cancer, 85(10), pp. 1551-1556. (doi: 10.1054/bjoc.2001.2138)

Stone, J. et al. (2001) Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in situ of the breast. Cancer Letters, 167(2), pp. 171-174. (doi: 10.1016/S0304-3835(01)00448-7)

Brooks, L., Tidy, J., Gusterson, B., Hiller, L., O'Nions, J., Gasco, M., Marin, M., Farrell, P., Kaelin, W. and Crook, T. (2000) Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Research, 60(24), pp. 6875-6877.

Ellis, I.O., Dowsett, M., Bartlett, J., Walker, R., Cooke, T., Gullick, W., Gusterson, B., Mallon, E. and Lee, P.B. (2000) Recommendations for HER2 testing in the UK. Journal of Clinical Pathology, 53(12), pp. 890-892.

Gusterson, B. and Howard, B. (2000) Human breast development. Journal of Mammary Gland Biology and Neoplasia, 5(2), pp. 119-137. (doi: 10.1023/A:1026487120779)

Mallon, E., Osin, P., Nasiri, N., Blain, I., Howard, B. and Gusterson, B. (2000) The basic pathology of human breast cancer. Journal of Mammary Gland Biology and Neoplasia, 5(2), pp. 139-163. (doi: 10.1023/A:1026439204849)

Book Sections

Gusterson, B.A., Cui, W. and Clark, A.K. (2003) Development of novel selective cell ablation in the mammary gland and to study cell-cell interactions and chemoprevention. In: Senn, H.J. and Morant, R. (eds.) Tumor Prevention and Genetics. Series: Recent Results in Cancer Research (163). Springer: Berlin, Germany, pp. 31-45. ISBN 9783540440628

This list was generated on Thu Sep 17 14:07:54 2020 BST.

Research datasets

Jump to: 2017
Number of items: 1.

2017

Olijnyk, D., Morris, J. , Stein, T. and Gusterson, B. (2017) Pubertal Ductal Morphogenesis: Isolation and Transcriptome Analysis of the Terminal End Bud. [Data Collection]

This list was generated on Sat Sep 25 18:19:50 2021 BST.